Table of Contents
1.Overview and Scope
1.1.Research goal & scope
1.2.Research assumptions
1.3.Research Methodology
1.3.1.Primary data sources
1.3.2.Secondary data sources
1.4.Key take-aways
1.5.Stakeholders
2.Executive Summary
2.1.Market Definition
2.2.Market Segmentation
3.Erectile dysfunction drugs Market Insights
3.1.Erectile dysfunction drugs– Industry snapshot
3.2.Erectile dysfunction drugs -Ecosystem analysis
3.3.Erectile dysfunction drugs market dynamics
3.3.1.Erectile dysfunction drugs– Market Forces
3.3.1.1.Erectile dysfunction drugs Market driver analysis
3.3.1.2.Erectile dysfunction drugs Market restraint/challenges analysis
3.3.1.3.Erectile dysfunction drugs Market opportunity analysis
3.3.2.Industry analysis - Porter's five force
3.3.2.1.Bargaining power of supplier
3.3.2.2.Bargaining power of buyer
3.3.2.3.Threat of substitute
3.3.2.4.Threat of new entrant
3.3.2.5.Degree of competition
3.3.3.Erectile dysfunction drugs market PEST analysis, 2017
3.3.4.Value Chain Analysis
3.3.5.Erectile dysfunction drugs Industry trends
3.3.6.Prevalence of erectile dysfunction
4.Erectile Dysfunction Drugs Market Size and Forecast by Product
4.1.Key findings
4.2.Viagra (Sildenafil citrate)
4.2.1.Global market estimates and forecasts, 2017 – 2025
4.3.Cialis (tadalafil)
4.3.1.Global market estimates and forecasts, 2017 – 2025
4.4.Levitra/Staxyn (vardenafil)
4.4.1.Global market estimates and forecasts, 2017 – 2025
4.5.Stendra/Spedra (avanafil)
4.5.1.Global market estimates and forecasts, 2017 – 2025
4.6.Zydena (udenafil)
4.6.1.Global market estimates and forecasts, 2017 – 2025
4.7.Vitaros (Alprostadil Cream)
4.7.1.Global market estimates and forecasts, 2017 – 2025
4.8.Others
4.8.1.Global market estimates and forecasts, 2017 – 2025
5.Erectile Dysfunction Drugs Market Size and Forecast by Component Type
5.1.Key findings
5.2.Testosterone
5.2.1.Global market estimates and forecasts, 2017 – 2025
5.3.Phosphodiestarse - 5 Inhibitors (PDE5I)
5.3.1.Global market estimates and forecasts, 2017 – 2025
5.4.Alprostadil
5.4.1.Global market estimates and forecasts, 2017 – 2025
5.5.Others
5.5.1.Global market estimates and forecasts, 2017 – 2025
6.Erectile Dysfunction Drugs Market Size and Forecast by Dosage Form
6.1.Key findings
6.2.Oral
6.2.1.Global market estimates and forecasts, 2017 – 2025
6.3.Topical
6.3.1.Global market estimates and forecasts, 2017 – 2025
6.4.Injections
6.4.1.Global market estimates and forecasts, 2017 – 2025
6.5.Others
6.5.1.Global market estimates and forecasts, 2017 – 2025
7.Erectile Dysfunction Drugs Market Size and Forecast by Distribution Channel
7.1.Key findings
7.2.Hospital Pharmacy
7.2.1.Global market estimates and forecasts, 2017 - 2025
7.3.Retail Pharmacy
7.3.1.Global market estimates and forecasts, 2017 – 2025
7.4.Online Pharmacy
7.4.1.Global market estimates and forecasts, 2017 - 2025
8.Erectile Dysfunction Drugs Market Size and Forecast by Regions
8.1.Key findings
8.2.North America
8.2.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.2.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.2.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.2.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.2.5.U.S.
8.2.5.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.2.5.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.2.5.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.2.5.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.2.6.Canada
8.2.6.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.2.6.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.2.6.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.2.6.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.2.7.Mexico
8.2.7.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.2.7.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.2.7.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.2.7.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.3.Europe
8.3.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.3.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.3.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.3.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.3.5.Germany
8.3.5.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.3.5.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.3.5.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.3.5.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.3.6.UK
8.3.6.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.3.6.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.3.6.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.3.6.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.4.Asia Pacific
8.4.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.4.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.4.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.4.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.4.5.China
8.4.5.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.4.5.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.4.5.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.4.5.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.4.6.India
8.4.6.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.4.6.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.4.6.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.4.6.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.4.7.Japan
8.4.7.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.4.7.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.4.7.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.4.7.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.5.Latin America
8.5.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.5.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.5.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.5.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.5.5.Brazil
8.5.5.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.5.5.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.5.5.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.5.5.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
8.6.Middle East & Africa
8.6.1.Erectile Dysfunction Drugs Market by Product (USD Million), 2017 - 2025
8.6.2.Erectile Dysfunction Drugs Market by Component type (USD Million), 2017 - 2025
8.6.3.Erectile Dysfunction Drugs Market by Dosage Form (USD Million), 2017 - 2025
8.6.4.Erectile Dysfunction Drugs Market by Distribution Channel (USD Million), 2017 - 2025
9.Company Profiles
9.1.Bayer AG
9.1.1.Overview
9.1.2.Financials
9.1.3.Drug Type Benchmarking
9.1.4.Recent Developments
9.2.Pfizer
9.2.1.Overview
9.2.2.Financials
9.2.3.Drug Type Benchmarking
9.2.4.Recent Developments
9.3.Eli Lilly & Co.,
9.3.1.Overview
9.3.2.Financials
9.3.3.Drug Type Benchmarking
9.3.4.Recent Developments
9.4.Vivus, Inc.
9.4.1.Overview
9.4.2.Financials
9.4.3.Drug Type Benchmarking
9.4.4.Recent Developments
9.5.S.K. Chemicals Co. Ltd.
9.5.1.Overview
9.5.2.Financials
9.5.3.Drug Type Benchmarking
9.5.4.Recent Developments
9.6.Dong-A Pharmaceutical Co. Ltd
9.6.1.Overview
9.6.2.Financials
9.6.3.Drug Type Benchmarking
9.6.4.Recent Developments
9.7.Meda Pharmaceuticals
9.7.1.Overview
9.7.2.Financials
9.7.3.Drug Type Benchmarking
9.7.4.Recent Developments
9.8.Apricus Biosciences
9.8.1.Overview
9.8.2.Financials
9.8.3.Drug Type Benchmarking
9.8.4.Recent Developments